Retroviral vectors for gene therapy

Since their first clinical trial 20 years ago, retroviral (gretroviral and lentiviral) vectors have now been used in more than 350 gene-therapy studies. Retroviral vectors are particularly suited for gene-correction of cells due to long-term and stable expression of the transferred transgene(s), and...

Full description

Saved in:
Bibliographic Details
Main Authors: Maier, Patrick (Author) , Kalle, Christof von (Author) , Maier-Laufs, Stephanie (Author)
Format: Article (Journal)
Language:English
Published: 12 Nov 2010
In: Future microbiology
Year: 2010, Volume: 5, Issue: 10, Pages: 1507-1523
ISSN:1746-0921
DOI:10.2217/fmb.10.100
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2217/fmb.10.100
Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/fmb.10.100
Get full text
Author Notes:Patrick Maier, Christof von Kalle, Stephanie Laufs
Description
Summary:Since their first clinical trial 20 years ago, retroviral (gretroviral and lentiviral) vectors have now been used in more than 350 gene-therapy studies. Retroviral vectors are particularly suited for gene-correction of cells due to long-term and stable expression of the transferred transgene(s), and also because little effort is required for their cloning and production. Several monogenic inherited diseases, mostly immunodeficiencies, can now be successfully treated. The occurrence of insertional mutagenesis in some studies allowed extensive analysis of integration profiles of retroviral vectors, as well as the design of lentiviral vectors with increased safety properties. These new-generation vectors will enable us to continue the successful story of gene therapy, and treat more patients and even more complex diseases.
Item Description:Gesehen am 02.05.2023
Physical Description:Online Resource
ISSN:1746-0921
DOI:10.2217/fmb.10.100